GlycoMimetics raises $15,400,000

GlycoMimetics, Inc. (GMI), a privately held firm that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced the successful completion of its Series B financing, attracting an additional $15.4-million to advance its research programs. The company’s initial focus is on therapeutics to treat inflammatory and infectious diseases